A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania

被引:14
|
作者
Perrin, E.
Anand, E. [1 ]
Dyachkova, Y.
Wagner, T. [2 ]
Frediani, S. [3 ]
Ballerini, A. [4 ]
机构
[1] Lilly Neurosci Res Ctr, Windlesham GU20 6PH, Surrey, England
[2] Lilly Deutschland GmbH, D-61350 Bad Homburg, Germany
[3] Psychiat Dept Venice, Natl Mental Hlth Serv, Venice, Italy
[4] Santa Maria Nuova Hosp, Serv Psichiatr Diagnosi & Cura, Florence, Italy
关键词
Agitation; Schizophrenia; Bipolar mania; IM psychotropic drugs; Acute dystonia; Akathisia; Parkinsonism; OLANZAPINE; MANAGEMENT; ANTIPSYCHOTICS; EFFICACY;
D O I
10.1016/j.eurpsy.2010.04.005
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
This naturalistic, observational pan-European study assessed the safety and early effectiveness of intramuscular (IM) psychotropic treatments in patients with acute agitation suffering from schizophrenia or bipolar mania. One thousand nine hundred and forty of 1945 patients completed the 24-hour observation period after initial IM treatment. Patients from 12 European countries were included (mean age 39 years; 58% male, 66% schizophrenia). IM treatment was at the physician's discretion. The primary objective was to describe the acute tolerability of IM psychotropic therapies in clinical practice, with particular emphasis on EPS. At baseline, 68% of the patients received IM monotherapy, with IM olanzapine most commonly prescribed (36%). During the first 24 hours, 190 (9.8%) patients experienced EPS. The occurrence of EPS was statistically significantly lower in patients treated with IM olanzapine compared to those treated with other IM psychotropic medications (mainly typical antipsychotics and benzodiazepines): acute dystonia: 1.1%, 95% CI 0.5-2.3 and 2.9%, CI 2.0-4.0; akathisia: 2.3%, CI 1.3-3.7 and 5.5%, CI 4.3-6.9; Parkinsonism: 2.9%, CI 1.8-4.4 and 7.8%, CI 6.4-9.4, respectively. Anticholinergic treatment was given to 12% IM olanzapine versus 31% non-olanzapine treated patients. Acute agitation after 24 hours was reduced by 1.68 (95% CI 1.46-1.91) points on the Clinical Global Impression of Severity (CGI-S) in IM olanzapine patients and 1.51 (95% CI 1.30-1.73) points in non-olanzapine patients. Additional psychotropic medication was required for 90% of the patients during the first 24 hours of treatment. Results provide naturalistic evidence for low EPS rates and improvement of agitation with IM psychotropic medications during acute states of patients suffering from acute mania or schizophrenia. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:234 / 239
页数:6
相关论文
共 50 条
  • [21] Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study
    Nanchen, David
    Carballo, David
    Bilz, Stefan
    Rickli, Hans
    Koskinas, Konstantinos C.
    Mach, Francois
    Mueller, Christian
    Crljenica, Carmela
    Rossi, Mariagrazia
    Reichert, Nina
    Sudano, Isabella
    ADVANCES IN THERAPY, 2022, 39 (01) : 504 - 517
  • [22] Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis
    Paris, Giulia
    Bighelli, Irene
    Deste, Giacomo
    Siafis, Spyridon
    Schneider-Thoma, Johannes
    Zhu, Yikang
    Davis, John M.
    Vita, Antonio
    Leucht, Stefan
    SCHIZOPHRENIA RESEARCH, 2021, 229 : 3 - 11
  • [23] A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia
    Peuskens, J.
    Bervoets, C.
    Kok, F.
    Delatte, B.
    Touquet, G.
    Gillain, B.
    de Patoul, A.
    Halkin, V.
    Loze, J. -Y.
    Vansteelandt, K.
    Constant, E.
    EUROPEAN PSYCHIATRY, 2012, 27 (07) : 506 - 512
  • [24] Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania
    Chandrasena, R.
    Dvorakova, D.
    Lee, S. I.
    Loza, N.
    Mosolov, S. N.
    Osvath, P.
    Pregelj, P.
    Walton, R. J.
    Karagianis, J.
    Treuer, T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (08) : 1249 - 1258
  • [25] Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia
    Meehan, KM
    Wang, HE
    David, SR
    Nisivoccia, JR
    Jones, B
    Beasley, CM
    Feldman, PD
    Mintzer, JE
    Beckett, LM
    Breier, A
    NEUROPSYCHOPHARMACOLOGY, 2002, 26 (04) : 494 - 504
  • [26] Comparison of Rapidly Acting Intramuscular Olanzapine, Lorazepam, and Placebo: A Double-blind, Randomized Study in Acutely Agitated Patients with Dementia
    Karena M Meehan
    Huei Wang
    Stacy R David
    Jennifer R Nisivoccia
    Barry Jones
    Charles M Beasley
    Peter D Feldman
    Jacobo E Mintzer
    Louise M Beckett
    Alan Breier
    Neuropsychopharmacology, 2002, 26 : 494 - 504
  • [27] Evaluating the Safety and Effectiveness of Alpha Blockers in the Treatment of Ureteric Stones: A Prospective Observational Study
    Hadia, Rajesh
    Chhatbar, Nishee
    Padiya, Priyanka
    Shah, Viram
    Patel, Siddhi
    Shah, Neel
    Rajput, Hemraj Singh
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2024, 14 (02) : 378 - 385
  • [28] Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study
    Vervloet, Marc G.
    Boletis, Ioannis N.
    de Francisco, Angel L. M.
    Kalra, Philip A.
    Ketteler, Markus
    Messa, Piergiorgio
    Stauss-Grabo, Manuela
    Derlet, Anja
    Walpen, Sebastian
    Perrin, Amandine
    Ficociello, Linda H.
    Rottembourg, Jacques
    Wanner, Christoph
    Cannata-Andia, Jorge B.
    Fouque, Denis
    CLINICAL KIDNEY JOURNAL, 2021, 14 (07) : 1770 - 1779
  • [29] A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod
    Mitsikostas, Dimos D. D.
    Orologas, Anastasios
    Dardiotis, Efthimios
    Fakas, Nikolaos
    Doskas, Triantafyllos
    Karageorgiou, Klimentini
    Maltezou, Maria
    Iliopoulos, Ioannis
    Vikelis, Michail
    Grigoriadis, Nikolaos
    ADVANCES IN THERAPY, 2023, 40 (05) : 2217 - 2233
  • [30] Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real-World Observational Study
    Brodeur, Sebastien
    Vanasse, Alain
    Courteau, Josiane
    Stip, Emmanuel
    Lesage, Alain
    Fleury, Marie-Josee
    Courteau, Mireille
    Roy, Marc-Andre
    ACTA PSYCHIATRICA SCANDINAVICA, 2022, 145 (05) : 456 - 468